dc.contributor.author | Thomas, NJ | |
dc.contributor.author | Hill, AV | |
dc.contributor.author | Dayan, CM | |
dc.contributor.author | Oram, RA | |
dc.contributor.author | McDonald, TJ | |
dc.contributor.author | Shields, BM | |
dc.contributor.author | Jones, AG | |
dc.contributor.author | StartRight Study Group | |
dc.date.accessioned | 2023-02-24T09:53:36Z | |
dc.date.issued | 2023-02-21 | |
dc.date.updated | 2023-02-24T06:20:21Z | |
dc.description.abstract | OBJECTIVE: To determine whether presentation, progression, and genetic susceptibility of robustly defined adult-onset type 1 diabetes (T1D) are altered by diagnosis age. RESEARCH DESIGN AND METHODS: We compared the relationship between diagnosis age and presentation, C-peptide loss (annual change in urine C-peptide-creatinine ratio [UCPCR]), and genetic susceptibility (T1D genetic risk score [GRS]) in adults with confirmed T1D in the prospective StartRight study, 1,798 adults with new-onset diabetes. T1D was defined in two ways: two or more positive islet autoantibodies (of GAD antibody, IA-2 antigen, and ZnT8 autoantibody) irrespective of clinical diagnosis (n = 385) or one positive islet autoantibody and a clinical diagnosis of T1D (n = 180). RESULTS: In continuous analysis, age of diagnosis was not associated with C-peptide loss for either definition of T1D (P > 0.1), with mean (95% CI) annual C-peptide loss in those diagnosed before and after 35 years of age (median age of T1D defined by two or more positive autoantibodies): 39 (31-46) vs. 44% (38-50) with two or more positive islet autoantibodies and 43 (33-51) vs. 39% (31-46) with clinician diagnosis confirmed by one positive islet autoantibody (P > 0.1). Baseline C-peptide and T1D GRS were unaffected by age of diagnosis or T1D definition (P > 0.1). In T1D defined by two or more autoantibodies, presentation severity was similar in those diagnosed before and after 35 years of age: unintentional weight loss, 80 (95% CI 74-85) vs. 82% (76-87); ketoacidosis, 24 (18-30) vs. 19% (14-25); and presentation glucose, 21 (19-22) vs. 21 mmol/L (20-22) (all P ≥ 0.1). Despite similar presentation, older adults were less likely to be diagnosed with T1D, insulin-treated, or admitted to hospital. CONCLUSIONS: When adult-onset T1D is robustly defined, the presentation characteristics, progression, and T1D genetic susceptibility are not altered by age of diagnosis. | en_GB |
dc.description.sponsorship | Diabetes UK | en_GB |
dc.description.sponsorship | National Institute for Health Research (NIHR) | en_GB |
dc.description.sponsorship | European Foundation for the Study of Diabetes | en_GB |
dc.format.extent | dc222159- | |
dc.identifier.citation | Published online 21 February 2023 | en_GB |
dc.identifier.doi | https://doi.org/10.2337/dc22-2159 | |
dc.identifier.grantnumber | 16/0005529 | en_GB |
dc.identifier.grantnumber | CS-2015-15-018 | en_GB |
dc.identifier.uri | http://hdl.handle.net/10871/132535 | |
dc.identifier | ORCID: 0000-0003-3581-8980 (Oram, Richard A) | |
dc.identifier | ORCID: 0000-0003-3559-6660 (McDonald, Timothy J) | |
dc.identifier | ORCID: 0000-0003-3785-327X (Shields, Beverley M) | |
dc.identifier | ORCID: 0000-0002-0883-7599 (Jones, Angus G) | |
dc.language.iso | en | en_GB |
dc.publisher | American Diabetes Association | en_GB |
dc.relation.source | Data Availability:
Data is available by contacting Dr Jones (angus.jones@exeter.ac.uk) | en_GB |
dc.relation.url | https://www.ncbi.nlm.nih.gov/pubmed/36802355 | en_GB |
dc.rights | © 2023, American Diabetes Association. Individual readers may use the content as long as the work is properly cited and linked to the version of record, the use is educational and not for profit, and the work is not altered. ADA permission is required to post articles on third-party websites or to include articles in educational materials that are sold to students or used in courses for which tuition or other fees are charged. | en_GB |
dc.title | Age of diagnosis does not alter the presentation or progression of robustly defined adult onset type 1 diabetes | en_GB |
dc.type | Article | en_GB |
dc.date.available | 2023-02-24T09:53:36Z | |
dc.identifier.issn | 0149-5992 | |
exeter.place-of-publication | United States | |
dc.description | This is the author accepted manuscript. The final version is available from the American Diabetes Association via the DOI in this record | en_GB |
dc.identifier.eissn | 1935-5548 | |
dc.identifier.journal | Diabetes Care | en_GB |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | en_GB |
dcterms.dateAccepted | 2023-01-19 | |
rioxxterms.version | AM | en_GB |
rioxxterms.licenseref.startdate | 2023-02-21 | |
rioxxterms.type | Journal Article/Review | en_GB |
refterms.dateFCD | 2023-02-24T09:48:56Z | |
refterms.versionFCD | AM | |
refterms.dateFOA | 2023-02-24T09:53:39Z | |
refterms.panel | A | en_GB |
refterms.dateFirstOnline | 2023-02-21 | |